Literature DB >> 33849849

Cohort profile: development and characteristics of a retrospective cohort of individuals dispensed prescription opioids for non-cancer pain in British Columbia, Canada.

James Wilton1, Mei Chong2, Younathan Abdia2,3, Roy Purssell2,4, Aaron MacInnes5,6, Tara Gomes7,8, Richard C Dart9,10, Robert F Balshaw11, Michael Otterstatter2,3, Stanley Wong2, Amanda Yu2, Maria Alvarez2, Naveed Zafar Janjua2,3, Jane A Buxton2,3.   

Abstract

PURPOSE: Prescription opioids (POs) are widely prescribed for chronic non-cancer pain but are associated with several risks and limited long-term benefit. Large, linked data sources are needed to monitor their harmful effects. We developed and characterised a retrospective cohort of people dispensed POs. PARTICIPANTS: We used a large linked administrative database to create the Opioid Prescribing Evaluation and Research Activities cohort of individuals dispensed POs for non-cancer pain in British Columbia (BC), Canada (1996-2015). We created definitions to categorise episodes of PO use based on a review of the literature (acute, episodic, chronic), developed an algorithm for inferring clinical indication and assessed patterns of PO use across a range of characteristics. FINDINGS TO DATE: The current cohort includes 1.1 million individuals and 3.4 million PO episodes (estimated to capture 40%-50% of PO use in BC). The majority of episodes were acute (81%), with most prescribed for dental or surgical pain. Chronic use made up 3% of episodes but 88% of morphine equivalents (MEQ). Across the acute to episodic to chronic episode gradient, there was an increasing prevalence of higher potency POs (hydromorphone, oxycodone, fentanyl, morphine), long-acting formulations and chronic pain related indications (eg, back, neck, joint pain). Average daily dose (MEQ) was similar for acute/episodic but higher for chronic episodes. Approximately 7% of the cohort had a chronic episode and chronic pain was the characteristic most strongly associated with chronic PO use. Individuals initiating a chronic episode were also more likely to have higher social/material deprivation and previous experience with a mental health condition or a problem related to alcohol or opioid use. Overall, these findings suggest our episode definitions have face validity and also provide insight into characteristics of people initiating chronic PO therapy. FUTURE PLANS: The cohort will be refreshed every 2 years. Future analyses will explore the association between POs and adverse outcomes. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  epidemiology; mental health; pain management; public health

Year:  2021        PMID: 33849849     DOI: 10.1136/bmjopen-2020-043586

Source DB:  PubMed          Journal:  BMJ Open        ISSN: 2044-6055            Impact factor:   2.692


  3 in total

1.  Patterns of prescription opioid dispensing among Red River Métis in Manitoba, Canada: a retrospective longitudinal cross-sectional study.

Authors:  Nathan C Nickel; Jennifer E Enns; Julianne Sanguins; Carrie O'Conaill; Dan Chateau; S Michelle Driedger; Carole Taylor; Gilles Detillieux; Miyosha Tso Deh; Emily Brownell; A Frances Chartrand; Alan Katz
Journal:  CMAJ Open       Date:  2022-03-29

2.  Association Between Prescription Opioid Therapy for Noncancer Pain and Hepatitis C Virus Seroconversion.

Authors:  James Wilton; Stanley Wong; Roy Purssell; Younathan Abdia; Mei Chong; Mohammad Ehsanul Karim; Aaron MacInnes; Sofia R Bartlett; Rob F Balshaw; Tara Gomes; Amanda Yu; Maria Alvarez; Richard C Dart; Mel Krajden; Jane A Buxton; Naveed Z Janjua
Journal:  JAMA Netw Open       Date:  2022-01-04

3.  Prescription opioid treatment for non-cancer pain and initiation of injection drug use: large retrospective cohort study.

Authors:  James Wilton; Younathan Abdia; Mei Chong; Mohammad Ehsanul Karim; Stanley Wong; Aaron MacInnes; Rob Balshaw; Bin Zhao; Tara Gomes; Amanda Yu; Maria Alvarez; Richard C Dart; Mel Krajden; Jane A Buxton; Naveed Z Janjua; Roy Purssell
Journal:  BMJ       Date:  2021-11-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.